These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8624271)

  • 1. A prognostic index for multiple myeloma.
    Grignani G; Gobbi PG; Formisano R; Pieresca C; Ucci G; Brugnatelli S; Riccardi A; Ascari E
    Br J Cancer; 1996 May; 73(9):1101-7. PubMed ID: 8624271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of bone marrow plasma cell infiltration in stage I multiple myeloma.
    Cavo M; Baccarani M; Gobbi M; Lipizer A; Tura S
    Br J Haematol; 1983 Dec; 55(4):683-90. PubMed ID: 6671088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multiple myeloma: a randomized study of three different regimens.
    Tribalto M; Amadori S; Cantonetti M; Franchi A; Papa G; Pileri A; Boccadoro M; Dammacco F; Vacca A; Centurioni R
    Leuk Res; 1985; 9(8):1043-9. PubMed ID: 3900591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio.
    Riccardi A; Montecucco C; Danova M; Ucci G; Merlini G; Ascari E
    Cancer Treat Rep; 1985 Sep; 69(9):971-5. PubMed ID: 4028038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Not Available].
    Hitz F
    Praxis (Bern 1994); 2016; 105(21):1255-1260. PubMed ID: 28573955
    [No Abstract]   [Full Text] [Related]  

  • 6. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
    J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma.
    Sakalová A; Holománová D; Mikulecký M; Mistrík M; Lipsic T; Steruská M
    Neoplasma; 1993; 40(6):351-4. PubMed ID: 8289966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.
    Riccardi A; Merlini G; Montecucco C; Danova M; Ucci G; Cassano E; Ascari E
    Eur J Cancer Clin Oncol; 1986 Jul; 22(7):787-91. PubMed ID: 3770037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response.
    Bettini R; Tonolini M; Bernasconi M
    Haematologica; 1998 Aug; 83(8):708-13. PubMed ID: 9793254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    Case DC; Lee DJ; Clarkson BD
    Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
    [No Abstract]   [Full Text] [Related]  

  • 11. Alternating intravenous courses of melphalan and peptichemio in high-risk multiple myeloma (preliminary results).
    Franchi F; Seminara P; Rossi Fanelli F
    Anticancer Res; 1986; 6(2):297-8. PubMed ID: 3707066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
    Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.
    Riccardi A; Ucci G; Luoni R; Brugnatelli S; Mora O; Spanedda R; De Paoli A; Barbarano L; Di Stasi M; Alberio F
    Br J Cancer; 1994 Dec; 70(6):1203-10. PubMed ID: 7981078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myelomatosis. A study of 138 patients treated with melphalan, prednisone and vincristine with particular attention to the prognostic value of a stage subdivision].
    Johnsen HE; Bergmann OJ; Boesen AM; Pedersen BB; Ellegaard J; Bastrup-Madsen P
    Ugeskr Laeger; 1989 Mar; 151(13):816-21. PubMed ID: 2718264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p170 protein in multiple myeloma: a clinical study.
    Ucci G; Petrini M; Riccardi A; Invernizzi R; Carulli G; Luoni R; Giordano M; Danova M
    Hematol Oncol; 1992; 10(3-4):213-20. PubMed ID: 1356905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
    Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
    J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Plasmocytic pleural effusion disclosing multiple myeloma].
    Elloumi M; Frikha M; Masmoudi H; Mseddi S; Ben Ayed M; Bouaziz M; Makni F; Souissi T
    Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.